Q1 Earnings Estimate for ACTU Issued By HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for Actuate Therapeutics in a research report issued on Monday, March 17th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.98) EPS.

Actuate Therapeutics Trading Down 4.9 %

ACTU stock opened at $6.99 on Wednesday. The firm has a 50-day moving average of $8.12 and a two-hundred day moving average of $8.06. Actuate Therapeutics has a 12 month low of $5.51 and a 12 month high of $11.73.

Institutional Investors Weigh In On Actuate Therapeutics

Large investors have recently made changes to their positions in the stock. Northwestern University purchased a new position in Actuate Therapeutics during the third quarter worth approximately $207,000. Sigma Planning Corp acquired a new stake in shares of Actuate Therapeutics in the 4th quarter worth $128,000. Freestone Capital Holdings LLC purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth $80,000. BIOS Capital Management LP purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth $78,753,000. Finally, Envestnet Asset Management Inc. acquired a new position in shares of Actuate Therapeutics during the 4th quarter valued at about $83,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.